Vascular Intervention Strategies Trial for Alzheimer's (VISTA)

Vascular Intervention Strategies Trial for Alzheimer's (VISTA)

The proposed pharmacist-led study is a feasibility pilot trial for the management of vascular risk factors of hypertension and hypercholesterolemia in 10 APOE ε4 carriers, 50-75, at-risk for dementia. All participants will receive angiotensin receptor blockers (ARBs) for high blood pressure, and hydrophilic statins (or a non-statin alternative) for high cholesterol over a six-month period.

Study Overview

• Status: Not yet recruiting
• Conditions: Hypertension; Hypercholesterolemia; Dementia Risk Factors
• Intervention / Treatment: Drug: Angiotensin Receptor Blockers (ARBs); Drug: Hydrophilic Statins or Non-Statin Alternative

• Study Type: Interventional
• Enrollment (Estimated): 10
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Hussein Yassine, MD; Phone Number: (323) 442-0272; Email: hyassine@usc.edu

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90033
      • Clinical Sciences Building (CSC)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• APOE ε4 carrier (homozygote or heterozygote)
• LDL-C of 100-250 mg/dL
• Systolic blood Pressure (SBP) 130-180 mm Hg
• Age 50-75 years
• Fluency in English
• No dementia based on medical record review
• Male or post-menopausal female

Exclusion Criteria:

• One minute standing SBP < 110 mm Hg
• Arm circumference prevents from accurate BP measurement with use of available devices
• Lost weight of > 10% unintendedly (within the past 6 months),
• Contraindications to blood pressure and cholesterol lowering medications
• Use of medications prescribed for dementia (e.g., aducanumab, donanemab, lecanemab, donepezil, galantamine, rivastigmine, memantine)
• Evidence of dementia based on medical record review
• Living in a skilled nursing or rehabilitation facility
• Receiving palliative or hospice care
• Bipolar illness or schizophrenia
• Drug or alcohol disorder
• Receiving chronic opioid therapy
• Any significant neurological disease (e.g., Parkinson's disease, amyotrophic lateral sclerosis, or multiple sclerosis)
• Severe loss of visual, hearing or communication ability
• Organ transplant
• History of stroke, symptomatic HF or left ventricular ejection fraction < 35%
• ESRD or eGFR < 20 ml/min /1.73m2
• Does not consent to be contacted or to have their medical record reviewed for research purposes
• Concurrent participation in another clinical trial

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Pharmacist-Led Vascular Risk Factor Management; Participants receive pharmacist-led management of hypertension and hypercholesterolemia using angiotensin receptor blockers and hydrophilic statins (or non-statin alternatives) over six months.

Drug: Angiotensin Receptor Blockers (ARBs); Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes blood pressure management with angiotensin receptor blockers (ARBs).; Drug: Hydrophilic Statins or Non-Statin Alternative; Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes cholesterol management with hydrophilic statins or a non-statin alternative if statins are not appropriate.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Blood Pressure Control	Change in systolic blood pressure (mmHg) from baseline to the end of the 6-month intervention.	Baseline to 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Lipid Level Changes	Change in LDL cholesterol (mg/dL) from baseline to 6 months.	Baseline to 6 months
Feasibility Metrics	adherence to prescribed medications (%).	Study duration (6 months)

Collaborators and Investigators

• Sponsor: University of Southern California

Study record dates

Study Major Dates

• Study Start (Estimated): May 1, 2026
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): June 1, 2028

Study Registration Dates

• First Submitted: February 25, 2026
• First Submitted That Met QC Criteria: February 25, 2026
• First Posted (Actual): March 3, 2026

Study Record Updates

• Last Update Posted (Actual): May 4, 2026
• Last Update Submitted That Met QC Criteria: April 27, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Hypertension; Hypercholesterolemia; Feasibility study; Vascular risk factors; Pharmacist-led intervention; APOE ε4 carriers; Dementia risk
• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Metabolic Diseases; Hyperlipidemias; Dyslipidemias; Lipid Metabolism Disorders; Nutritional and Metabolic Diseases; Hypertension; Hypercholesterolemia; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Angiotensin Receptor Antagonists
• Other Study ID Numbers: HS-24-00340; PG1040967 (Other Grant/Funding Number: University of Southern California)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No